US general population sample | VA outpatient sample | ||||||
---|---|---|---|---|---|---|---|
(N = 26,610) | (N = 467,416) | ||||||
Men | |||||||
Positive screen based on AUDIT-C score | |||||||
AUDIT-C score | % reporting < recommended limits | ||||||
Total | Q#1 | Q#2 | Q#3 | % | (95% CI) | % | (95% CI) |
4 | 3 | 1 | 0 | 2.3 | (2.1–2.6) | 1.0 | (1.0-1.0) |
4 | 4 | 0 | 0 | 5.4 | (5.1–5.8) | 12.9 | (12.7–13.0) |
5 | 4 | 1 | 0 | 1.1 | (0.9–1.3) | 1.9 | (1.8–1.9) |
All inconsistent positive screens | 8.9* | (8.4–9.4) | 15.8 | (15.6–15.8) | |||
Negative screen based on AUDIT-C score | |||||||
AUDIT-C score | % reporting > recommended limits | ||||||
Total | Q#1 | Q#2 | Q#3 | % | (95% CI) | % | (95% CI) |
2 | 1 | 0 | 1 | 1.1 | (0.9–1.2) | 2.0 | (2.0–2.0) |
3 | 1 | 1 | 1 | 2.0 | (1.7–2.2) | 0.6 | (0.6–0.6) |
3 | 1 | 0 | 2 | 0 | -- | 0.3 | (0.3–0.3) |
3 | 1 | 2 | 0 | 0 | -- | 0.1 | (0.01-0.1) |
3 | 2 | 0 | 1 | 1.9 | (1.7–2.2) | 2.3 | (2.2–2.3) |
All inconsistent negative screens | 4.9 | (4.6–5.3) | 5.3 | (5.2–5.3) | |||
All inconsistent negative & positive screens | 13.8 | (13.2–14.4) | 21.1 | (20.9–21.1) | |||
Women | |||||||
Positive screen based on AUDIT-C score | |||||||
AUDIT-C score | % reporting < recommended limits ** | ||||||
Total | Q#1 | Q#2 | Q#3 | % | (95% CI) | % | (95% CI) |
3 | 2 | 1 | 0 | 2.6 | (2.4–2.9) | 1.5 | (1.3–1.7) |
3 | 3 | 0 | 0 | 8.2 | (7.7–8.6) | 8.1 | (7.7–8.5) |
4 | 3 | 1 | 0 | 1.6 | (1.4–1.8) | 0.6 | (0.5–0.8) |
4 | 4 | 0 | 0 | 5.0 | (4.6–5.4) | 7.2 | (6.8–7.6) |
All inconsistent positive screens | 17.5* | (16.8–18.1) | 17.4 | (16.9–18.0) | |||
Negative screen based on AUDIT-C score | |||||||
AUDIT-C score | % reporting > recommended limits | ||||||
Total | Q#1 | Q#2 | Q#3 | % | (95% CI) | % | (95% CI) |
2 | 1 | 0 | 1 | 0.8 | (0.7–1.0) | 3.3 | (3.0–3.6) |
All inconsistent negative screens | 0.8 | (0.7–1.0) | 3.3 | (3.0–3.6) | |||
All inconsistent negative & positive screens | 18.3* | (17.7–18.9) | 20.7 | (20.1–21.3) |